Cipar -
grčki -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
rythmonorm 300mg film coated tablets
mylan ire healthcare limited (0000010616) unit 35/36, grange parade, baldoyle industrial estate, dublin 13 - propafenone hydrochloride - film coated tablets - 300mg - propafenone hydrochloride (0034183227) 300mg - propafenone
Cipar -
grčki -
Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας
rythmonorm 150mg film coated tablets
viatris healthcare limited. (0000012172) damastown industrial park, mulhuddart, dublin 15, d15 xd71 - propafenone hydrochloride - film coated tablets - 150mg - propafenone hydrochloride (0034183227) 150mg - propafenone
Njemačka -
njemački -
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
quinkon
abbott gmbh & co. kg (3081097) - propafenonhydrochlorid - injektionslösung - propafenonhydrochlorid 0.070g
Kanada -
francuski -
Health Canada
propafenone-150 comprimé
pro doc limitee - chlorhydrate de propafénone - comprimé - 150mg - chlorhydrate de propafénone 150mg - class ic antiarrythmics
Kanada -
francuski -
Health Canada
propafenone-300 comprimé
pro doc limitee - chlorhydrate de propafénone - comprimé - 300mg - chlorhydrate de propafénone 300mg - class ic antiarrythmics
Kanada -
engleski -
Health Canada
propafenone-150 tablet
pro doc limitee - propafenone hydrochloride - tablet - 150mg - propafenone hydrochloride 150mg - class ic antiarrythmics
Kanada -
engleski -
Health Canada
propafenone-300 tablet
pro doc limitee - propafenone hydrochloride - tablet - 300mg - propafenone hydrochloride 300mg - class ic antiarrythmics
Kanada -
engleski -
Health Canada
nu-propafenone tablet
nu-pharm inc - propafenone hydrochloride - tablet - 150mg - propafenone hydrochloride 150mg - class ic antiarrythmics
Sjedinjene Američke Države -
engleski -
NLM (National Library of Medicine)
propafenone- propafenone hydrochloride capsule, extended release
rebel distributors corp - propafenone (unii: 68iqx3t69u) (propafenone - unii:68iqx3t69u) - propafenone 325 mg - propafenone extended release capsules are indicated to prolong the time to recurrence of symptomatic atrial fibrillation in patients without structural heart disease. the use of propafenone er capsules in patients with permanent atrial fibrillation or in patients exclusively with atrial flutter or psvt has not been evaluated. propafenone er capsules should not be used to control ventricular rate during atrial fibrillation. the effect of propafenone er capsules on mortality has not been determined (see black box warnings ). propafenone er capsules are contraindicated in the presence of congestive heart failure, cardiogenic shock, sinoatrial, atrioventricular and intraventricular disorders of impulse generation or conduction (e.g., sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker, bradycardia, marked hypotension, bronchospastic disorders, electrolyte imbalance, or hypersensitivity to the drug.